| Market Cap | 6.04M | P/E | - | EPS this Y | 81.60% | Ern Qtrly Grth | - |
| Income | -11.6M | Forward P/E | -0.40 | EPS next Y | 34.80% | 50D Avg Chg | -49.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -56.00% |
| Dividend | N/A | Price/Book | 0.66 | EPS next 5Y | - | 52W High Chg | -82.00% |
| Recommedations | 2.00 | Quick Ratio | 1.33 | Shares Outstanding | 2.55M | 52W Low Chg | 12.00% |
| Insider Own | 0.07% | ROA | -140.03% | Shares Float | 2.55M | Beta | 0.24 |
| Inst Own | 5.59% | ROE | -366.18% | Shares Shorted/Prior | 16.35K/55.27K | Price | 0.76 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 132,850 | Target Price | 20.00 |
| Oper. Margin | - | Earnings Date | Nov 13 | Volume | 997,978 | Change | -22.53% |
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.
| Roth MKM | Buy | Jul 8, 24 |
| Roth MKM | Buy | Apr 18, 24 |
| Roth MKM | Buy | Mar 27, 24 |